Tenderwize
Wróć do wyszukiwania

Open-house Lenograstim rebate agreement

Techniker Krankenkasse·Hamburg, Germany·Deadline Dec 30, 2027 · 492 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-30 - Lenograstim

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...

Participation is restricted to pharmaceutical undertakings for the relevant product, with seat and authorisation requir...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Conclusion of rebate agreements for the active substance Lenograstim under an open-house procedure.
  • Supply of pharmaceutical products (CPV 33600000).
Pokaż pełne podsumowanie

Open-house supply arrangement for Lenograstim pharmaceutical products in Germany, led by Techniker Krankenkasse with HEK and hkk participating. The notice states no exclusivity, no individual negotiations, and uniform terms for all eligible pharmaceutical companies. Contracting can occur throughout the term, but the agreement ends no later than 31.12.2027. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, with portal communication used for questions. No contract value is stated.

Ryzyka

Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...

Participation is restricted to pharmaceutical undertakings for the relevant product, with seat and authorisation requir...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal products.
  • Applicant must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-house Lenograstim rebate agreement

Open-house contract for pharmaceutical rebate agreements under Section 130c(1) SGB V for the active substance Lenograstim. Scope is nationwide in Germany. The lot information comes from structured data and the notice text.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Dec 2025 - Dec 2027

Kategoria

Pharmaceutical products

Termin

Deadline Dec 30, 2027

Szczegóły zamówienia

Data publikacji
23 Apr 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
282722-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3